Lead Product(s): COVID-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Vaccine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 06, 2021
Under the terms of the agreement, Cristal Therapeutics and Intravacc will collaborate with an initial focus on generating a CriVac® vaccine candidate based on the receptor-binding domain of the SARS-CoV-2 spike protein.